By: IPP Bureau
Last updated : September 16, 2025 4:43 pm
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
Atom Therapeutics, a clinical-stage biotechnology company focused on developing best-in-class treatments for inflammatory and metabolic diseases, announced that it has enrolled the first patient in its multicenter, global Phase 2 clinical trial of ABP-745. This investigational oral therapy is being developed for the treatment of painful acute gout flares.
The randomized, double-blind study will enroll more than 200 patients across sites in the United States, China, and Australia. The trial is designed to evaluate the safety, efficacy, and pharmacodynamics of ABP-745 in reducing the pain and swelling associated with acute gout flares. Patients will receive either ABP-745, placebo, or colchicine—the current standard of care for gout flares.
“This milestone builds on the successful completion of our U.S. Phase 1 trial, which demonstrated that ABP-745 is safe and well tolerated,” said Dr. William Dongfang Shi, Founder, Chairman and CEO of Atom Therapeutics. “ABP-745 was created as a new chemical entity to improve efficacy and safety compared to existing therapies, with the added benefit of avoiding key drug–drug interactions seen with colchicine.”
While acute gout flares are the first indication for ABP-745, the drug’s broad inhibitory activity against inflammatory mediators—including IL-1β, TNF-α, IL-6, and IL-18—positions it as a promising candidate for development in additional conditions such as cardiovascular disease.
Gout, one of the most common types of inflammatory arthritis, affects more than 60 million people worldwide, including an estimated 12 million patients in the US.
In addition to ABP-745, Atom Therapeutics is advancing its lead program, lingdolinurad (ABP-671), an oral URAT1 inhibitor currently in Phase 2b/3 global trials for chronic gout. ABP-671 has achieved its primary endpoint of lowering serum uric acid levels while demonstrating a favorable safety and tolerability profile, positioning it as a potential best-in-class therapy for chronic gout.
“With both ABP-745 and ABP-671, Atom is building a comprehensive pipeline to address the full spectrum of gout and its complications, while also advancing therapies that may benefit broader inflammatory and metabolic diseases,” Dr. Shi added.